Influence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibility

Carcinogenesis

Volumn 17, Issue 10, 1996, Pages 2267-2269

  Legrand, M ^a   Stucker I ^b   Marez, D ^a   Sabbagh, N ^a   Lo Guidice, J M ^a   Broly, F ^a  

^a UNIV LILLE   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME;

ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; CATALYSIS; CIGARETTE SMOKING; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; HISTOLOGY; HOSPITAL; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK; SINGLE STRAND CONFORMATION POLYMORPHISM; SMALL CELL CARCINOMA;

ALLELES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CATALYSIS; CYTOCHROME P-450 CYP2D6; EXONS; HUMANS; LUNG NEOPLASMS; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029802706     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.10.2267     Document Type: Article

References (28)

1. Eichelbaum, M., Baur, M.P., Dengler, H.J., Osikowska-Evers, B.O., Tieves, G., Zekorn, C. and Rittner, C. (1987) Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br. J. Clin. Pharmacol., 23, 455-458.
2. Gonzalez, F.J., Vilbois, F., Hardwick, J.P., McBride, O.W., Nebert, D.W., Gelboin, H.V. and Meyer, U.A. (1988) Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics, 2, 174-179.
3. Kimura, S., Umeno, M., Skoda, R.C., Meyer, U.A. and Gonzalez, F.J. (1989) Human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet., 45, 889-904.
4. Crespi, C.L., Penman, B.W., Gelboin, H.V. and Gonzalez, F.J. (1991) A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis, 12, 1197-1201.
5. Daly, A.K., Cholerton, S., Gregory, W. and Idle, J.R. (1993) Metabolic polymorphisms. Pharmacol Ther., 57, 129-160.
6. Llerena, A., Edman, G., Cobaleda, J., Benitez, J., Schalling, D. and Bertilsson, L. (1993) Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiat. Scand., 87, 23-28.
7. Sindrup, S.H., Poulsen, L., Brøsen, K., Arendt-Nielsen, L. and Gram, L.F. (1993) Are poor metabolizers of sparteine/debrisoquine less pain tolerant than extensive metabolizers. Pain, 53, 335-339.
8. Skoda, R.C., Gonzalez, F.J., Demierre, A. and Meyer, U.A. (1988) Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc. Natl Acad. Sci. USA, 85, 5240-5243.
9. Gonzalez, F.J., Skoda, R.C., Kimura, S., Umeno, M., Zanger, U.M., Nebert, D.W., Gelboin, H.V., Hardwick, J.P. and Meyer, U.A. (1988b) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 331, 442-446.
10. Nebert, D.W. (1991) Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk. Cancer Cells, 3, 93-96.
11. Gonzalez, F.J. (1995) Genetic polymorphism and cancer susceptibility: Fourteenth Sapporo Cancer Seminar. Cancer Res., 55, 710-715.
12. Daly, A.K., Brockmöller, J., Broly, F. et al. (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6, 193-201.
13. Heim, M. and Meyer, U.A. (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet, 336, 529-532.
14. Steen, V.M., Andreassen, O.A., Daly, A.K., Tefre, T., Børresen, A.L., Idle, J.R. and Gulbrandsen, A.K. (1995) Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics, 5, 215-223.
15. Bell, D.A. (1991) Detection of DNA sequence polymorphisms in carcinogen metabolism genes by polymerase chain reaction. Environ. Mol. Mutagen., 18, 245-248.
16. Broly, F., Gaedigk, A., Heim, M., Eichelbaum, M., Morike, K. and Meyer, U.A. (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 8, 545-558.
17. Tyndale, R., Aoyama, T., Broly, F., Matsunaga, T., Inaba, T., Kalow, W., Gelboin, H.V., Meyer, U.A. and Gonzalez, F.J. (1991) Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics, 1, 26-32.
18. Wolf, C.R., Smith, C.A.D., Gough, A.C. et al. (1992) Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis, 13, 1035-1038.
19. Buchert, E.T., Woosley, R.L., Swain, S.M., Oliver, S.J., Coughlin, S.S., Pickle, L., Trock, B. and Riegel, A.T. (1993) Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility. Pharmacogenetics, 3, 322-327.
20. Idle, J.R. and Daly, A.K. (1993) New opportunities in cancer risk evaluation using PCR-based DNA analysis for CYP2D6. Environ. Health Perspect., 101 (Suppl. 3), 117-120.
21. Agundez, J.A.G., Ledesma, M.C., Benitez, J., Ladero, J.M., Rodriguez-Lescure, A., Diaz-Rubio, E. and Diaz-Rubio, M. (1995) CYP2D6 genes and risk of liver cancer. Lancet, 345, 830-831.
22. Agundez, J.A.G., Martinez, C., Ladero, J.M., Ledesma, M.C., Ramos, J.M., Martin, R., Rodriguez, A., Jara, C. and Benitez, J. (1994) Debrisoquin oxidation genotype and susceptibility to lung cancer. Clin. Pharmacol. Ther., 55, 10-4.
23. Broly, F. and Meyer, U.A. (1993) Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics, 3, 123-130.
24. Broly, F., Marez, D., Sabbagh, N., Legrand, M., Millecamps, S., Lo-Guidice, J.M., Boone, P. and Meyer, U.A. (1995) An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics, 5, 373-384.
25. Stücker, I., Cosme, J., Laurent, Ph., Cenée, S., Beaune, Ph., Bignon, J., Depierre, A., Milleron, B. and Hémon, D. (1995) CYP2D6 genotype and lung cancer risk according to histologie type and tobacco exposure. Carcinogenesis, 16, 2759-2764.
26. Broly, F., Marez, D., Lo Guidice, J.M., Sabbagh, N., Legrand, M., Boone, P. and Meyer, U.A. (1995) A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Hum. Genet., 96, 601-603.
27. Marez, D., Sabbagh, N., Legrand, M., Lo-Guidice, J.M., Boone, P. and Broly, F. (1995) A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics, 5, 305-311.
28. Marez, D., Legrand, M., Sabbagh, N., Lo-Guidice, J.M., Boone, P. and Broly, F. (1996) An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Hum. Genet., 97, 668-670.